Management of menopausal symptoms

Obstetrics and Gynecology

Volumn 126, Issue 4, 2015, Pages 859-876

  Kaunitz, Andrew M ^a   Manson, Joann E ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; GESTAGEN; NON PRESCRIPTION DRUG; OSPEMIFENE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE;

ARTICLE; BEHAVIOR THERAPY; BREAST CANCER; DISEASE DURATION; DRUG SAFETY; EARLY MENOPAUSE; ENDOMETRIOSIS; ESTROGEN THERAPY; FEMALE; GENE MUTATION; HORMONAL THERAPY; HUMAN; HYPNOSIS; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MENOPAUSE; META ANALYSIS (TOPIC); PATIENT HISTORY OF HYSTERECTOMY; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STELLATE GANGLION BLOCK; TREATMENT DURATION; UROGENITAL TRACT DISEASE; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; ADRENERGIC SYSTEM; DRUG EFFECTS; FEMALE UROGENITAL DISEASES; HOT FLASHES; MIDDLE AGED;

ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMALE UROGENITAL DISEASES; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; VASOMOTOR SYSTEM;

EID: 84942755623     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000001058     Document Type: Article

References (90)

1. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014;21:924-32.
2. North American Menopause Society. Menopause practice: a clinician's guide. 5th ed. Mayfield Heights (OH): NAMS; 2014.
3. Nelson HD. Menopause. Lancet 2008;371:760-70.
4. Freedman RR. Physiology of hot flashes. AmJ Hum Biol 2001; 13:453-64.
5. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985;22:293-312.
6. Freedman RR Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. AmJ Obstet Gynecol 1999;181:66-70.
7. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006;96:1226-35.
8. Sievert LL. Menopause across cultures: clinical considerations. Menopause 2014;21:421-3.
9. Brown DE, Sievert LL, Morrison LA, Reza AM, Mills PS. Do Japanese American women really have fewer hot flashes than European Americans? The Hilo Women's Health Study. Menopause 2009;16:870-6.
10. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117:1095-104.
11. Pinkerton JV, Wilson CS. Perspectives on the first randomized sham-controlled trial of stellate ganglion block for hot flashes. Menopause 2014;21:788-91.
12. Elkins GR Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2013;20:291-8.
13. Dodin S, Blanchet C, Marc I, Ernst E, Wu T, Vaillancourt C, et al. Acupuncture for menopausal hot flushes. The Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD007410. DOI: 10.1002/14651858.CD007410.pub2.
14. Moilanen JM, Mikkola TS, Raitanen JA, Heinonen RH, Tomas EI, Nygård CH, et al. Effect of aerobic training on menopausal symptoms-a randomized controlled trial. Menopause 2012;19:691-6.
15. Sternfeld B, Guthrie KA, Ensrud KE, LaCroix AZ, Larson JC, Dunn AL, et al. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause 2014;21:330-8.
16. Carpenter JS, Burns DS, Wu J, Otte JL, Schneider B, Ryker K, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. J Gen Intern Med 2013;28:193-200.
17. Saensak S, Vutyavanich T, Somboonporn W, Srisurapanont M. Effectiveness of a modified version of the applied relaxation technique in treatment of perimenopausal and postmenopausal symptoms. IntJ Womens Health 2013;5:765-71.
18. Carmody JF, Crawford S, Salmoirago-Blotcher E, Leung K, Churchill L, Olendzki N. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause 2011;18: 611-20.
19. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145:869-79.
20. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. The Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD001395. DOI: 10.1002/14651858.CD001395.pub4.
21. Cohen LS, Joffe H, Guthrie KA, Ensrud KE, Freeman M, Carpenter JS, et al. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Menopause 2014;21:347-54.
22. North American Menopause Society. The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause 2012;19:257-71.
23. Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians Gynecologists. Obstet Gynecol 2014;123:202-16.
24. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
25. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus pro-gestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-48.
26. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353-68.
27. Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009;114:1197-204.
28. Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxypro-gesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-5.
29. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. The Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD002978. DOI: 10.1002/14651858.CD002978.pub2.
30. Pinkerton JV, Harvey JA, Lindsay R, Pan K, Chines AA, Mirkin S, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin En-docrinol Metab 2014;99:E189-98.
31. Pinkerton JV, Harvey JA, Pan K, Thompson JR, Ryan KA, Chines AA, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 2013; 121:959-68.
32. Kaunitz AM. Transdermal and vaginal estradiol for the treatment of menopausal symptoms: the nuts and bolts. Menopause 2012;19:602-3.
33. Santoro N, Stephens S. Glob. libr. women's med. (ISSN: 1756-2228) 2012. DOI: 10.3843/GLOWM.10083.
34. Depypere H, Inki P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric 2015;18:470-82.
35. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 2011;306:1884-90.
36. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7.
37. Writing Group on behalf of Workshop Consensus Group. Aging, menopause, cardiovascular disease and HRT. International Menopause Society Consensus Statement. Climacteric 2009;12:368-77.
38. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(suppl 1):s1-S66.
39. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53: 605-19.
40. Bray PF, Larson JC, Lacroix AZ, Manson J, Limacher MC, Rossouw JE, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008;101:1599-1605.
41. Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, et al. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 2013;20:254-60.
42. Manson JE. The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. Metabolism 2013;62(suppl 1):S15-9.
43. Bassuk SS, Manson JE. Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification. Clin Chem 2014;60:68-77.
44. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.
45. Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J, et al. Testing the menopausal hormone therapy timing hypothesis: the Early versus Late Intervention Trial with Estradiol. Circulation 2014;130:A13283.
46. Rossouw J, Manson JE, Kaunitz AM, Stefanick ML. Study had insufficient power to investigate safety. BMJ 2012;345:e8146.
47. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249-60.
48. Manson JE, Ames JM, Shapiro M, Gass ML, Shifren JL, Stuenkel CA, et al. Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society. Menopause 2014;22: 247-53.
49. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(suppl 2): S49-73.
50. Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 2013;103:1583-8.
51. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31.
52. Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Committee Opinion No. 556. American College of Obstetricians Gynecologists. Obstet Gynecol 2013;121:887-90.
53. Rott H. Prevention and treatment of venous thromboembo-lism during HRT: current perspectives. Int J Gen Med 2014;7: 433-40.
54. Kaunitz AM. Extended duration use of menopausal hormone therapy. Menopause 2014;21:679-81.
55. Pinkerton JV, Santoro N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause Epub 2015 Feb 17.
56. Kaunitz AM, Kaunitz JD. Compounded bioidentical hormone therapy: time for a reality check? Menopause Epub 2015Jun 1.
57. Pinkerton JV. What are the concerns about custom-compounded 'bioidentical' hormone therapy? Menopause 2014;21:1298-300.
58. Timmer CJ, Geurts TB. Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study. Eur J Drug Metab Pharmacokinet 1999;24:47-53.
59. Cherry N, McNamee R Heagerty A, Kitchener H, Hannaford P. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG 2014;121: 700-5.
60. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estro-gen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996;275:370-5.
61. Steiner AZ, Xiang M, Mack WJ, Shoupe D, Felix JC, Lobo RA, et al. Unopposed estradiol therapy in postmenopausal women: results from two randomized trials. Obstet Gynecol 2007;109: 581-7.
62. Dood RL, Gracia CR Sammel MD, Haynes K, Senapati S, Strom BL. Endometrial cancer after endometrial ablation vs medical management of abnormal uterine bleeding. J Minim Invasive Gynecol 2014;21:744-52.
63. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri-and postmenopausal women. The Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD004509. DOI: 10.1002/14651858.CD004509.pub2.
64. Kingsberg SA, Woodard T. Female sexual dysfunction: focus on low desire. Obstet Gynecol 2015;125:477-86.
65. Huang G, Basaria S, Travison TG, Ho MH, Davda M, Mazer NA, et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause 2014;21: 612-23.
66. Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw 2010;8:1171-9.
67. Simon JA Portman DJ, Kaunitz AM, Mekonnen H, Kazempour K Bhaskar S, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027-35.
68. Joffe H, Guthrie KA LaCroix AZ, Reed SD, Ensrud KE, Manson JE, et al. Low-dose estradiol and the serotoninnorepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058-66.
69. Walega DR Rubin LH, Banuvar S, Shulman LP, Maki PM. Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women. Menopause 2014;21:807-14.
70. Jewett PI, Gangnon RE, Trentham-Dietz A, Sprague BL. Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010. Obstet Gynecol 2014;124:727-33.
71. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762-74.
72. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21:1063-8.
73. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902.
74. Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014;124:1147-56.
75. Manson JE, Goldstein SR, Kagan R, Kaunitz AM, Liu JH, Pinkerton JV, et al. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause 2014;21:911-6.
76. Simon JA, Lin VH, Radovich C, Bachmann GA;, Ospemifene Study Group. One-year long-term safety extension study of ospe-mifene for the treatment of vulvar and vaginal atrophy in post-menopausal women with a uterus. Menopause 2013;20:418-27.
77. Rebar RW. Premature ovarian failure. Obstet Gynecol 2009; 113:1355-63.
78. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357-63.
79. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-62.
80. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-82.
81. von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005;97:533-5.
82. Management of gynecologic issues in women with breast cancer. Practice Bulletin No. 126. American College of Obstetricians Gynecologists.Obstet Gynecol 2012;119:666-82.
83. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354-60.
84. Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:1547-53.
85. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:7804-10.
86. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361-7.
87. Domchek SM, Friebel T, Neuhausen SL, Lynch HT, Singer CF, Eeles RA, et al. Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)-and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? J Clin Oncol 2011;29:1501.
88. Olié V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:488-93.
89. Giudice LC. Clinical practice. Endometriosis. N Engl J Med 2010;362:2389-98.
90. Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, et al. Managing menopause [in English, French]. J Obstet Gynaecol Can 2014;36:830-8.